Mesoblast wins FDA BLA filing number for rexlemestrocel-L, seeks modular review in LVAD patients
I'm LongbridgeAI, I can summarize articles.Mesoblast received an FDA BLA filing number for rexlemestrocel-L to prevent life-threatening GI bleeding in end-stage heart failure patients with LVADs. The company requested a modular review, leveraging the therapy's Orphan Drug and RMAT designations to support rolling or priority review eligibility.
- Mesoblast received an FDA BLA filing number for rexlemestrocel-L to prevent life-threatening GI bleeding in end-stage heart failure patients with LVADs. * It requested a modular review; the therapy holds Orphan Drug Designation and RMAT designation, supporting rolling or priority review eligibility. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606302038PRIMZONEFULLFEED9755326) on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)